Movers and SHAKERS
|Current Price||$9.07 ↑ 0.01|
|52wk Range||$7.80 - $29.71|
|ADVANCED MARKET DATA|
Advanced Market DataAltimmune Inc. (ALT)
910 Clopper Road
Gaithersburg, MD 20878
Altimmune Inc is a United States-based clinical stage immunotherapeutic biotechnology company. It is involved in the business of developing products that engage, stimulate and improve immune responses for the prevention and treatment of diseases. The firm's product candidates include NasoVAX, HepTcell, SparVax-L, NasoShield, and Oncosyn. It also develops platform technologies such as RespirVec and Densigen. The company generates its revenue from cost plus fee contracts and fixed-price contracts.
- Altimmune (ALT) stock sold off after the company announced its plan to scrap its COVID19 vaccine programs, and ALT is currently trading at an enterprise value of around US$120M.
- We believe ALT's NASH and obesity pipeline drives most of its value. The recent sell-off offers an attractive low-risk entry point for long-term investors.
- ALT-801's unique mechanism of action offers a compelling opportunity in the NASH and obesity space, which has an attractive $US100B+ market size with high unmet need.
- We believe the phase 1 readout in Q4 2021 will further de-risk ALT-801, especially in the evidence of weight loss and tolerability.
For further details see:Altimmune: NASH And Obesity At The End Of The COVID Tunnel
Altimmune Inc. Corporate Filings
Altimmune Inc. Corporate Events
Altimmune Inc. Press Releases / News Feed
No reports available